학술논문
In-situ immune markers predict nivolumab (N) plus /-ipilimumab (I) efficacy in frontline metastatic clear cell renal cell carcinoma (mccRCC): Key ancillary analyses from the BIONIKK randomized trial
Document Type
Journal
Author
Source
Subject
Language
English
ISSN
15698041